Sector News

Pfizer to shutter two UK sites

November 10, 2016
Life sciences

Drugs giant Pfizer has announced plans to close two of its three key UK supply sites, but insists the decision has nothing to do with Brexit.

According to media reports, the firm’s manufacturing site in Park Royal, London, as well as its global cold chain packaging and distribution facility in Portsmouth will be closed in 2017 and 2020 respectively, with around 370 job losses in total.

“This review process has been going on since 2010 and the team just felt there were more production capabilities at the site in Belgium to support future demand and to ensure we can support the supply chain,” explained a spokesman for the firm, as reported by The Telegraph.

“The UK has a tricky commercial environment and doesn’t always link life sciences investment to the way patients use medicines, but this decision is not linked to Brexit or medicines access”.

Pfizer sold its flagship UK facilities in Sandwich, Kent, back in 2012, but around 700 of its employees remain employed at the Discovery Park science and business hub which is now housed there, and it still currently employs around 2,700 people at sites across the country.

By Selina McKee

Source: Pharma Times

comments closed

Related News

May 21, 2022

As monkeypox cases emerge in US and Europe, Bavarian Nordic inks vaccine order

Life sciences

A monkeypox outbreak is emerging in the U.S. and Europe, and at least one country is amping up countermeasure preparedness. Bavarian Nordic has secured a contract with an unnamed European country to supply its smallpox vaccine, called Imvanex in Europe, in response to the emergence of monkeypox cases, the Danish company said Thursday.

May 21, 2022

Moderna chairman Afeyan defends hiring practices after CFO debacle: report

Life sciences

Moderna’s recent chief financial officer debacle—in which Jorge Gomez departed on his second day on the job—raised questions about the company’s hiring process given its rush to global biopharma prominence. The most obvious one: How was it possible for Gomez to be hired when he was under investigation by his previous employer, Dentsply Sirona of Charlotte, N.C.

May 21, 2022

Merck to pay up to $1.4B in cancer deal with Kelun, but details are scarce

Life sciences

Merck & Co. is plucking a cancer project from the branch of Chinese-based Kelun Pharmaceutical for up to $1.4 billion, but details from the New Jersey-based Big Pharma have been hard to come by. The deal, first disclosed Monday on the Shenzhen stock exchange, has Merck handing over $47 million in upfront cash in exchange for ex-China rights to a “macromolecular tumor project.”